Cassava Pharma (SAVA) - צמיחת רווח למניה בשנה הנוכחית

Cassava Sciences, Inc. (SAVA) price action is tied to clinical trial results, which isolates it from macroeconomic influence. The annual EPS change scale demonstrates a support level where the value has stabilized at -32.60. Management's persistence in court and hopes for FDA approval are cushioning the decline, despite massive expenditures and the risk of failure in Alzheimer's disease research.
פילוחי מדדים פיננסיים ומדדי שוק עבור Cassava Sciences Inc (SAVA)

This metric measures the annual dynamics of net income per share, reflecting the impact of global liquidity on equity value. For Cassava Sciences, Inc. (SAVA), the absence of proprietary manufacturing facilities and the outsourcing of trials make this parameter sensitive to operational costs associated with contractors. By analyzing the percentage deviation of EPS from the previous year, an investor can discern the actual growth rate of profitability. Sharp spikes in this indicator often signal a market overpayment. This is a key tool for the fundamental assessment of business model efficiency.